长链非编码RNA ASB16-AS1与垂体腺瘤患者预后的关系  

The relationship of long non-coding RNA ASB16-AS1 with pituitary adenomas prognosis

作　　者：晋涛 郑慧军[2] JIN Tao;ZHENG Hui-jun(Department of Neurosurgery,Zhengzhou Yihe Hospital Affiliated to Henan University,Zhengzhou,Henan 450047;Department of Neurosurgery,Henan Province Hospital of Traditional Chinese Medicine,Zhengzhou,Henan 450002,China)

机构地区：[1]河南大学附属郑州颐和医院神经外科,河南郑州450047 [2]河南省中医院神经外科,河南郑州450002

出　　处：《热带医学杂志》2022年第2期175-178,211,共5页Journal of Tropical Medicine

基　　金：2019年度河南省中医药科学研究专项课题(2019ZY2052)。

摘　　要：目的 探讨垂体腺瘤患者肿瘤组织中长链非编码RNA(lncRNA)ASB16-AS1表达水平与临床病理特征及预后的关系。方法 选取2015年8月-2017年8月于河南大学附属郑州颐和医院住院治疗的114例垂体腺瘤患者肿瘤组织作为垂体腺瘤组,选取各垂体腺瘤患者正常垂体组织作为对照组。采用实时荧光定量PCR(qRT-PCR)法检测垂体腺瘤患者肿瘤组织及正常垂体组织lncRNA ASB16-AS1表达水平;分析垂体腺瘤患者肿瘤组织lncRNA ASB16-AS1表达水平与预后的关系以及影响垂体腺瘤患者预后的因素。结果 垂体腺瘤组lncRNA ASB16-AS1表达水平(2.39±0.41)高于对照组(1.01±0.24),差异有统计学意义(t=27.998,P<0.05)。有功能肿瘤、肿瘤最大径>2 cm、有侵袭性、病理分级Ⅲ~Ⅳ级垂体腺瘤患者lncRNA ASB16-AS1高表达比例高于无功能肿瘤、肿瘤最大径≤2 cm、无侵袭性、病理分级Ⅰ~Ⅱ级患者,差异有统计学意义(P<0.05)。lncRNA ASB16-AS1高表达组垂体腺瘤患者3年生存率(44.83%)低于lncRNA ASB16-AS1低表达组(85.71%),差异有统计学意义(χ^(2)=20.912,P<0.05)。lncRNA ASB16-AS1、病理分级是影响垂体腺瘤患者预后死亡的独立危险因素(P<0.05)。结论 垂体腺瘤患者肿瘤组织中lncRNA ASB16-AS1表达水平升高,lncRNA ASB16-AS1在垂体腺瘤的发生、发展及不良预后中可能起促进作用。Objective To investigate the relationship between the expression levels of long non-coding RNA(lncRNA)ASB16-AS1 and clinicopathological features and prognosis of pituitary adenomas.Methods From August 2015 to August2017,114 cases of pituitary tumor tissues in Zhengzhou Yihe Hospital Affiliated to Henan University were selected as pituitary tumor group;normal pituitary tissues of patients with pituitary adenomas were used as control group.The expression level of lncRNA ASB16-AS1 in tumor tissues and normal pituitary tissues were detected by real-time fluorescent quantitative PCR(q RT-PCR);the relationship between lncRNA ASB16-AS1 expression with prognosis and the prognostic factors of pituitary adenoma patients was analyzed.Results The expression level of lncRNA ASB16-AS1 in pituitary adenoma group(2.39±0.41)was significantly higher than that in control group(1.01±0.24)(t=27.998,P<0.05).The high expression rates of lncRNA ASB16-AS1 in patients with functional tumor,tumor maximum diameter >2 cm,invasive pituitary tumor and pathological grade Ⅲ-Ⅳ was higher than those in patients with non functional tumor,tumor maximum diameter ≤2 cm,non-invasive pituitary tumor and pathological grade Ⅰ-Ⅱ(P<0.05).The 3-year survival rate of patients with pituitary adenomas in high lncRNA ASB16-AS1 expression group(44.83%)was lower than that in low lncRNA ASB16-AS1 expression group(85.71%),and the difference was statistically significant(χ^(2)=20.912,P<0.05).LncRNA ASB16-AS1 and pathological grade were independent risk factors for prognostic death in patients with pituitary adenoma(P<0.05).Conclusions The expression level of lncRNA ASB16-AS1 was increased in pituitary tumor tissues.LncRNA ASB16-AS1 might play a promoting role in the occurrence,development and poor prognosis of pituitary tumor.

关 键 词：垂体腺瘤 长链非编码RNA ASB16-AS1 临床病理特征 

分 类 号：R736.4[医药卫生—肿瘤]